FINANCE REPORT OF SUN PHARMA

Global revenues of Sun Pharmaceutical Industries Ltd. (Sun Pharma) exceed US$ 4.5 billion, making it
the world's fourth largest specialty generic pharmaceutical company. More than 100 countries
around the world rely on their multi-faceted manufacturing capabilities to provide patients and
healthcare professionals with affordable, high-quality medicines.

VISION

Reaching People and Touching Lives Globally As A Leading Provider Of Valued Medicines

VALUES

• Quality

Get it right the first time

• Reliability

Maintain efficiency & discipline in all processes & systems and fulfil the promises made to
stakeholders

• Trust

Be transparent in dealings

• Consistency

Endeavour to bring new products to the market & consistently deliver value to stakeholders

• Innovation

Implement new ideas & technologies to meet unmet needs and think ahead of times

MILESTONE

2021

• We launched ILUMYA™ (tildrakizumab injection), a treatment for adults living with

moderate-to-severe plaque psoriasis in Canada
• We launched a speciality dermatology product, WINLEVI® (clascoterone) cream 1% in the
U.S. for topical treatment of Acne Vulgaris
• We forayed into the nutrition bar segment in India with the launch of Revital NXT, India’s
first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple
blend protein

AWARDS & RECOGNITION

2021
 • We received the Golden Peacock Award for Corporate Social Responsibility, 2020
• We won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based
category- Pharmaceuticals
• We bagged the DIANA (Distribution Industry Award for Notable Achievements in Healthcare)
award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution
Alliance Conference 2021
• We were recognized as the Best Innovative Company of the Year 2021 at Indo-American
Corporate Excellence Awards.

BOARD OF DIRECTORS

Name Designation

Aalok Shanghvi Senior Vice President

Abhay Gandhi CEO - North America

Anilkumar Jain CEO - API Business

Azadar H Khan Senior Vice President

C S Muralidharan Chief Financial Officer

Davinder Singh Senior Vice President

Dilip S Shanghvi Managing Director

Gautam Doshi Ind. Non-Executive Director

Hellen de Kloet Business Head

Israel Makov Chairman

Jila Breeze Senior Vice President & Global Head

Kalyanasundaram Subramanian Whole Time Director

Kirti Ganorkar CEO - India Business

Pawan Goenka Independent Director

Pradeep Sanghvi Executive Vice President

Rama Bijapurkar Independent Director

Rekha Sethi Ind. Non-Executive Director

Sailesh T Desai Whole Time Director

Sapna Purohit Senior Vice President & Head - HR

Sreenivas Rao Senior Vice President & Head

Sudhir V Valia Non Exe.Non Ind.Director

Sunil R Ajmera Company Secretary

Vivek Chaand Sehgal Ind. Non-Executive Director

Shareholding Pattern

Holder's Name No of Shares % Share Holding

No of Shares 2399334970 100%

Promoters 1307134535 54.48%

Foreign Institutions 311795611 13%

Bank Mutual Funds 283015073 11.8%

Central Govt 6430 0%

Others 116280080 4.85%

General Public 160321568 6.68%

Financial Institutions 220781673 9.2%

FINANCIAL STATEMENT

Profit & Loss Rs (in Crores)

Mar'21 Mar'20

12Months 12Months

INCOME:

Sales Turnover 12803.21 12531.93

Excise Duty .00 .00

NET SALES 12803.21 12531.93

Other Income 150.2200 1510.9200

TOTAL INCOME 12953.43 14042.85

EXPENDITURE:

Manufacturing Expenses 384.13 394.74

Material Consumed 5190.54 4942.40

Personal Expenses 1798.45 1702.77

Selling Expenses .00 .00

Administrative Expenses 2494.09 2780.37

Expenses Capitalised .00 .00

Provisions Made .00 .00

TOTAL EXPENDITURE 9867.21 9820.28

Operating Profit 2936.00 2711.65

EBITDA 3086.22 4222.57

Depreciation 586.81 561.56

Other Write-offs .00 .00

EBIT 2499.41 3661.01

Interest 256.98 408.01

EBT 2242.43 3253.00

Taxes 13.17 41.86

Profit and Loss for the Year 2229.26 3211.14

Non Recurring Items -96.82 -18.63

Other Non Cash Adjustments .00 .00

Other Adjustments 7.26 18.63

REPORTED PAT 2139.70 3211.14

KEY ITEMS

Preference Dividend .00 .00

Equity Dividend 1559.06 1186.07

Equity Dividend (%) 649.80 494.34

Shares in Issue (Lakhs) 23993.35 23993.35

EPS - Annualised (Rs) 8.92 13.38

Rs (in Crores)

BALANCE SHEET: click here

FINANCIAL RATIOS

RATIOS 2021 2020

DEBT-EQUITY RATIO 0.26 0.27

CURRENT RATIO 1.31 1.00

ASSET TURNOVER RATIO 1.50 1.60

INVENTORY TURNOVER RATIO 4.42 4.62

DEBTORS TURNOVER RATIO 2.04 2.24

INTEREST COVERAGE RATIO 9.38 8.97

OPERATING MARGIN (%) 23.41 33.69

NET PROFIT MARGIN (%) 16.71 25.62

RETURN ON CAPITAL EMPLOYED (%) 7.43 11.85

RETURN ON NET WORTH (%) 8.66 13.60